000126568 001__ 126568
000126568 005__ 20240228140833.0
000126568 0247_ $$2doi$$a10.1002/ijc.29322
000126568 0247_ $$2pmid$$apmid:25387692
000126568 0247_ $$2ISSN$$a0020-7136
000126568 0247_ $$2ISSN$$a1097-0215
000126568 0247_ $$2altmetric$$aaltmetric:2886128
000126568 037__ $$aDKFZ-2017-02596
000126568 041__ $$aeng
000126568 082__ $$a610
000126568 1001_ $$0P:(DE-He78)cce6b51dcd85173b43b8b662ea47c700$$aGardyan, Adriane$$b0$$eFirst author$$udkfz
000126568 245__ $$aIdentification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.
000126568 260__ $$aBognor Regis$$bWiley-Liss$$c2015
000126568 3367_ $$2DRIVER$$aarticle
000126568 3367_ $$2DataCite$$aOutput Types/Journal article
000126568 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523948040_20700
000126568 3367_ $$2BibTeX$$aARTICLE
000126568 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126568 3367_ $$00$$2EndNote$$aJournal Article
000126568 520__ $$aBreast cancer represents the second most common cancer type worldwide and has remained the leading cause of cancer-related deaths among women. The differentiation antigen NY-BR-1 appears overexpressed in invasive mammary carcinomas compared to healthy breast tissue, thus representing a promising target antigen for T cell based tumor immunotherapy approaches. Since efficient immune attack of tumors depends on the activity of tumor antigen-specific CD4(+) effector T cells, NY-BR-1 was screened for the presence of HLA-restricted CD4(+) T cell epitopes that could be included in immunological treatment approaches. Upon NY-BR-1-specific DNA immunization of HLA-transgenic mice and functional ex vivo analysis, a panel of NY-BR-1-derived library peptides was determined that specifically stimulated IFNγ secretion among splenocytes of immunized mice. Following in silico analyses, four candidate epitopes were determined which were successfully used for peptide immunization to establish NY-BR-1-specific, HLA-DRB1*0301- or HLA-DRB1*0401-restricted CD4(+) T cell lines from splenocytes of peptide immunized HLA-transgenic mice. Notably, all four CD4(+) T cell lines recognized human HLA-DR-matched dendritic cells (DC) pulsed with lysates of NY-BR-1 expressing human tumor cells, demonstrating natural processing of these epitopes also within the human system. Finally, CD4(+) T cells specific for all four CD4(+) T cell epitopes were detectable among PBMC of breast cancer patients, showing that CD4(+) T cell responses against the new epitopes are not deleted nor inactivated by self-tolerance mechanisms. Our results present the first NY-BR-1-specific HLA-DRB1*0301- and HLA-DRB1*0401-restricted T cell epitopes that could be exploited for therapeutic intervention against breast cancer.
000126568 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000126568 588__ $$aDataset connected to CrossRef, PubMed,
000126568 650_7 $$2NLM Chemicals$$aAntigens, Neoplasm
000126568 650_7 $$2NLM Chemicals$$aEpitopes, T-Lymphocyte
000126568 650_7 $$2NLM Chemicals$$aHLA-DRB1 Chains
000126568 650_7 $$2NLM Chemicals$$aHLA-DRB1*03:01 antigen
000126568 650_7 $$2NLM Chemicals$$aHLA-DRB1*04:01 antigen
000126568 650_7 $$2NLM Chemicals$$aPeptide Library
000126568 650_7 $$2NLM Chemicals$$abreast cancer antigen NY-BR-1, human
000126568 650_7 $$082115-62-6$$2NLM Chemicals$$aInterferon-gamma
000126568 7001_ $$0P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aOsen, Wolfram$$b1$$udkfz
000126568 7001_ $$0P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aZörnig, Inka$$b2$$udkfz
000126568 7001_ $$0P:(DE-HGF)0$$aPodola, Lilli$$b3
000126568 7001_ $$0P:(DE-HGF)0$$aAgarwal, Maria$$b4
000126568 7001_ $$aAulmann, Sebastian$$b5
000126568 7001_ $$0P:(DE-He78)606957afb35b517e3fdd526379767c48$$aRuggiero, Eliana$$b6$$udkfz
000126568 7001_ $$0P:(DE-He78)b91bec47a4148ba68a58ab292d5860f2$$aSchmidt, Manfred$$b7$$udkfz
000126568 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b8$$udkfz
000126568 7001_ $$0P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aLeuchs, Barbara$$b9$$udkfz
000126568 7001_ $$0P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$avon Kalle, Christof$$b10$$udkfz
000126568 7001_ $$0P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aBeckhove, Philipp$$b11$$udkfz
000126568 7001_ $$aSchneeweiss, Andreas$$b12
000126568 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b13$$udkfz
000126568 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b14$$eLast author$$udkfz
000126568 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.29322$$gVol. 136, no. 11, p. 2588 - 2597$$n11$$p2588 - 2597$$tInternational journal of cancer$$v136$$x0020-7136$$y2015
000126568 909CO $$ooai:inrepo02.dkfz.de:126568$$pVDB
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cce6b51dcd85173b43b8b662ea47c700$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)606957afb35b517e3fdd526379767c48$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b91bec47a4148ba68a58ab292d5860f2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000126568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000126568 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000126568 9141_ $$y2015
000126568 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126568 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126568 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126568 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126568 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000126568 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126568 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126568 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126568 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126568 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126568 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126568 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000126568 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x0
000126568 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x1
000126568 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x2
000126568 9201_ $$0I:(DE-He78)F010-20160331$$kF010$$lTumorvirologie$$x3
000126568 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x4
000126568 9201_ $$0I:(DE-He78)G183-20160331$$kG183$$lPräklinische T-Zellforschung$$x5
000126568 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x6
000126568 980__ $$ajournal
000126568 980__ $$aVDB
000126568 980__ $$aI:(DE-He78)D015-20160331
000126568 980__ $$aI:(DE-He78)D120-20160331
000126568 980__ $$aI:(DE-He78)G100-20160331
000126568 980__ $$aI:(DE-He78)F010-20160331
000126568 980__ $$aI:(DE-He78)G010-20160331
000126568 980__ $$aI:(DE-He78)G183-20160331
000126568 980__ $$aI:(DE-He78)G182-20160331
000126568 980__ $$aUNRESTRICTED